Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2002

View Archived Issues

Life Medical Sciences given green light for trial of Repel-CV in neonatal patients

Patients enrolling in pivotal PRIMO-CABG trial

ICN files IND for viramidine

Telik updates progress of TLK-286

Abgenix submits IND for ABX-MA1 in metastatic melanoma

Marketing approval obtained for Replagal in Israel, Switzerland and Czech Republic

Geron and Genetic Therapy enter licensing agreement to develop cancer therapy

Fungicidal peptides derived from an active BPI fragment at Xoma

Noncytotoxic, semisynthetic milbemycin inhibits fungal efflux pump in Candida

Pharmacokinetics/metabolism of new oxazolidinone PNU-173995 reported at ICAAC

Naphthyridinone-based FabI/FabK inhibitor with good oral activity in animal infection model

ICAAC presentations cover development of BB-83698, a new peptide deformylase inhibitor

Genencor and Johns Hopkins form strategic research collaboration

Study demonstrates safety, preliminary efficacy of squalamine as 120-hour infusion

SkyePharma signs agreement to develop HFA-based Pulmicort systems

Metalloelastase inhibitors reported by Shionogi to have potential in COPD, etc.

Anti-HIV agents designed by Janssen and reported in patent literature

Agonists at the alpha7 nicotinic acetylcholine receptor claimed by Novartis

Antitumor activity demonstrated for new series of caprolactam carbonates

New growth hormone secretagogues and their use described by BMS

AstraZeneca patents novel neuropeptide Y5 receptor antagonists

Millennium initiates phase I clinical program of MLN-341 in combination with Taxotere

InterMune's Actimmune receives fast track designation for idiopathic pulmonary fibrosis

Idec's BLA for Zevalin radioimmunotherapy approvable according to FDA

Emisphere completes enrollment in PROTECT trial of oral heparin

Study protocol changes following early positive results for Gleevec in CML

Successful results from Cubist's proof-of-principle study with oral ceftriaxone